Seqens Unveils Innovation and Development CoE

Seqens, a provider of pharmaceutical synthesis and specialty ingredients, has opened a 366,000-square-foot lab close to Paris, France that will serve as the company’s center of excellence in its Porcheville facility. Known as SEQENS'Lab, the new lab offers a package of R&D services, dedicated to accelerate projects from early research and development stages to production and sales for clients in key markets including pharmaceuticals, cosmetics and specialty ingredients.
 
Agnès Pannier-Runacher, Secretary of State to the Minister of Economy and Finance, will attend the ribbon-cutting for the SEQENS’Lab in her official capacity in charge of industry to show support for research in France, particularly in pharmaceuticals and health.
 
Part of a strategic corporate initiative to expand offerings and capabilities throughout the Seqens network, the SEQENS’Lab will also be available to customers of Seqens North America (formerly PCI Synthesis).
 
As an R&D center that meets the highest standards, SEQENS’Lab has assembled the group’s key skills and expertise in recognized areas of excellence, such as: organic chemistry development at the forefront of the latest innovations, two referring laboratories in physics and solid-state chemistry as well as in process safety, kinetic and thermodynamic simulation tools, large batch manufacturing capabilities for preclinical and clinical studies, all in an environment that adheres to cGMP.
 
In addition, it has means for developing future processes, particularly in flow chemistry.
 
SEQENS’Lab will host innovative SMBs specialized in analytical services and CROs, giving Seqens customers access to complementary skills in one place. For example, long-term partner GenEvolution brings key skills to SEQENS’Lab in toxicology for medicine, chemical ingredients, plant extracts and cosmetic ingredient evaluation.
 
 "The SEQENS’Lab is a world-class innovation and development center dedicated to our customers to accelerate their projects," said Pierre Luzeau, chief executive officer, Seqens Group. "It is also dedicated to our teams, this center is theirs too, and is part of a strategic expansion of our capabilities and resources." 

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com